NCT02267603 - Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 25, 2014

Primary Completion Date

February 6, 2018

Study Completion Date

December 15, 2021

Conditions

Recurrent Merkel Cell CarcinomaStage III Merkel Cell Carcinoma AJCC v7Stage IIIA Merkel Cell Carcinoma AJCC v7Stage IIIB Merkel Cell Carcinoma AJCC v7Stage IV Merkel Cell Carcinoma AJCC v7

Interventions

OTHER

Laboratory Biomarker Analysis

Ancillary studies

BIOLOGICAL

Pembrolizumab

Given IV

Trial Locations (13)

10029

Mount Sinai Hospital, New York

15232

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh

21287

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

27710

Duke University Medical Center, Durham

30322

Emory University Hospital/Winship Cancer Institute, Atlanta

33612

Moffitt Cancer Center, Tampa

43210

Ohio State University Comprehensive Cancer Center, Columbus

70112

Louisiana State University Health Science Center, New Orleans

University Medical Center New Orleans, New Orleans

94115

UCSF Medical Center-Mount Zion, San Francisco

94304

Stanford Cancer Institute Palo Alto, Palo Alto

98109

Seattle Cancer Care Alliance, Seattle

06520

Yale University, New Haven

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH